Headache News and Research

Latest Headache News and Research

Positive results from Vertex VX-770 Phase 3 trial against CF

Vertex Pharmaceuticals Incorporated today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

30 Mar 2011

Consumption of popular pain reliever during pregnancy may put children at increased risk for asthma

A new study published in the journal Clinical & Experimental Allergy reveals that children whose mothers used the popular pain reliever paracetamol during pregnancy were at an increased risk of wheezing when compared to non-users.

28 Mar 2011

Panax ginseng, saffron and yohimbine can boost human sexual function

Looking to spice up your sex life? Try adding ginseng and saffron to your diet. Both are proven performance boosters, according to a new scientific review of natural aphrodisiacs conducted by University of Guelph researchers.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Genentech, a member of the Roche Group, announced today that the second of two Phase III trials evaluating Lucentis in patients with diabetic macular edema met its primary endpoint.

28 Mar 2011

Pregnant women can benefit from low-to-moderate intensity weight-training program

Despite decades of doctors' reluctance to recommend weight training to pregnant women, a new University of Georgia study has found that a supervised, low-to-moderate intensity program is safe and beneficial.

28 Mar 2011

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Bayer HealthCare Pharmaceuticals Inc. today announced that interim results from a large, prospective, observational cohort safety study offer insights into the increased risk of venous thromboembolism (VTE), or blood clots, which is a well-established risk in women who use combination oral contraceptives (COCs), also known as "the Pill".

25 Mar 2011

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Physicians from Purdue Pharma LP, Stamford, CT, showcased study results that demonstrate the analgesic efficacy and safety of Butrans for the relief of moderate to severe chronic low back pain in opioid-naive patients. Butrans is a transdermal delivery system that provides systemic delivery of buprenorphine, a Schedule III medication, continuously over a 7-day period.

25 Mar 2011

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.

25 Mar 2011

Study finds risk of heart attack among patients with TIA

Patients who have suffered a "mini stroke" are at twice the risk of heart attack than the general population, according to research reported in Stroke: Journal of the American Heart Association.

25 Mar 2011

Merck & Co receives FDA approval for Zostavax vaccine to treat shingles

The Food and Drug Administration today approved the use of Zostavax, a live attenuated virus vaccine, for the prevention of shingles in individuals 50 to 59 years of age. Zostavax is already approved for use in individuals 60 years of age and older.

25 Mar 2011

Mosquitoes carry risk of Murray Valley encephalitis warn Victorian health authorities

After detecting some new cases of Murray Valley encephalitis in chickens, health authorities have warned Victorians to protect themselves from mosquito bites. Victoria's chief health officer, Dr John Carnie warned that the deadly disease had been detected in "sentinel" chickens at Cobram, Rutherglen, Toolamba and Bendigo. “These latest detections follow positive results in chickens in similar areas a month ago, including Barmah and Kerang… Evidence of the virus is again present in these areas,” Dr Carnie said.

24 Mar 2011

Aradigm fourth quarter revenue is $144,000 for 2010

Aradigm Corporation today announced financial results for the fourth quarter and full year ended December 31, 2010.

24 Mar 2011

Cilag, POZEN enter license agreement to develop and commercialize MT 400

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that it has entered into a license agreement with Cilag GmbH International, a division of Johnson & Johnson, for the development and commercialization of MT 400 in Brazil, Colombia, Ecuador and Peru.

23 Mar 2011

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

ViroPharma Incorporated today announced data presented in two poster presentations relating to Cinryze at the 2011 American Academy of Allergy Asthma & Immunology Annual Meeting, March 18 through 22, in San Francisco, CA.

23 Mar 2011

POZEN files motion for Treximet patent litigation against Par

POZEN Inc., a pharmaceutical company committed to transforming medicines that transform lives, today announced that it has filed a motion for a preliminary injunction seeking to prevent Par Pharmaceuticals, Inc. from launching a generic version of Treximet.

23 Mar 2011

Positive results from Meda's Dymista Phase III trial in patients with SAR

Meda announced today positive results from a Phase III clinical trial of Dymista, a novel formulation of azelastine hydrochloride and fluticasone propionate, in patients with seasonal allergic rhinitis.

22 Mar 2011

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Shire plc, the global specialty biopharmaceutical company, presented new data for Replagal in patients with Fabry disease, and VPRIV in patients with type 1 Gaucher disease, at the 2011 American College of Medical Genetics' Annual Clinical Genetics Meeting, held in Vancouver, BC, from March 16-20, 2011.

22 Mar 2011

CSL Behring presents Hizentra study data against PI at AAAAI meeting

Data presented by CSL Behring today suggest that treatment with higher dose Hizentra correlates with reduced risk of infection and missed school or work among patients with primary immunodeficiencies.

22 Mar 2011

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

XenoPort, Inc. announced today preliminary top-line results from a Phase 2b clinical trial of arbaclofen placarbil (also known as AP) as adjunctive therapy in patients with gastroesophageal reflux disease (GERD) who do not experience complete relief of GERD symptoms while being treated with proton pump inhibitors (PPI).

21 Mar 2011

Headache News and Research

Latest Headache News and Research

Positive results from Vertex VX-770 Phase 3 trial against CF

Consumption of popular pain reliever during pregnancy may put children at increased risk for asthma

Panax ginseng, saffron and yohimbine can boost human sexual function

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Genentech's Lucentis Phase III trials in DME meets primary endpoints

Pregnant women can benefit from low-to-moderate intensity weight-training program

Study finds increased risk of VTE during first year of combination oral contraceptive usage

Purdue demonstrates efficacy of Butrans transdermal delivery system for chronic pain in opioid-naive patients

Positive top-line results from Targacept's TC-5619 Phase 2 trial in adults with ADHD

Study finds risk of heart attack among patients with TIA

Merck & Co receives FDA approval for Zostavax vaccine to treat shingles

Mosquitoes carry risk of Murray Valley encephalitis warn Victorian health authorities

Aradigm fourth quarter revenue is $144,000 for 2010

Cilag, POZEN enter license agreement to develop and commercialize MT 400

ViroPharma presents Cinryze data against HAE at AAAAI Annual Meeting

POZEN files motion for Treximet patent litigation against Par

Positive results from Meda's Dymista Phase III trial in patients with SAR

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

CSL Behring presents Hizentra study data against PI at AAAAI meeting

XenoPort reports preliminary top-line results from arbaclofen placarbil Phase 2b clinical trial in GERD

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in